Richard Carpenter, MD
Family Medicine · Elloree, SCNPI 1376600486
Payments from drug & device makers
Across 65 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$262
- Novo Nordisk$168
- Lilly USA, LLC$107
- Sanofi-aventis U.S. LLC$74
- Boehringer Ingelheim$60
- AbbVie$56
- plus $428 from 17 others
What the payments were for
- Food & beverage$1,155100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $262 |
| Novo Nordisk | 13 | $168 |
| Lilly USA, LLC | 7 | $107 |
| Sanofi-aventis U.S. LLC | 2 | $74 |
| Boehringer Ingelheim | 3 | $60 |
| AbbVie(2 entities) | 3 | $56 |
| GSK | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Johnson & Johnson | 3 | $42 |
| Shire North American Group Inc | 2 | $36 |
| Dexcom, Inc. | 1 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Merck | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Viatris Specialty LLC | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $21 |
| Abbott | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Amgen | 1 | $16 |
| Novartis | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$1,155 in reported general payments places this provider in the 60th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 249 | $295,928 |
| FarxigaDapagliflozin Propanediol | 231 | $168,534 |
| JardianceEmpagliflozin | 152 | $143,629 |
| EliquisApixaban | 174 | $131,627 |
| Tresiba Flextouch U-100Insulin Degludec | 153 | $118,740 |
| TrulicityDulaglutide | 70 | $92,844 |
| JanuviaSitagliptin Phosphate | 71 | $80,762 |
| OzempicSemaglutide | 68 | $76,899 |
| XareltoRivaroxaban | 66 | $67,335 |
| LinzessLinaclotide | 97 | $63,507 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 64 | $53,027 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $49,340 |
| RybelsusSemaglutide | 32 | $38,902 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $24,881 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $22,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $107 | $388,772319 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $262 | $205,590314 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat, Stiolto Respimat | $60 | $191,155207 claims |
| MerckJanuvia, Janumet Xr, Janumet | $27 | $158,670170 claims |
| PfizerEliquis, Lyrica | $13 | $141,239185 claims |
| Novo NordiskOzempic, Rybelsus, Tresiba | $168 | $123,986112 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $44 | $67,35093 claims |
| Johnson & JohnsonXarelto | $42 | $67,33566 claims |
| AbbVieLinzess | $56 | $63,50797 claims |
| NovartisEntresto | $14 | $13,42520 claims |
| Sanofi-aventis U.S. LLCMultaq | $74 | $9,00512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Elloree
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.